- Reata Pharmaceuticals press release ( NASDAQ: RETA ): Q2 Non-GAAP EPS of -$1.36 beats by $0.61 .
- Revenue of $0.76M (-65.8% Y/Y) misses by $0.7M .
- On June 30, 2022, we had cash and cash equivalents and marketable securities of $481.5 million, as compared to $590.3 million on December 31, 2021.
- The Company reaffirms its existing cash & cash equivalents and marketable debt securities will be sufficient to enable it to fund operations through the end of 2024.
For further details see:
Reata Pharmaceuticals Non-GAAP EPS of -$1.36 beats by $0.61, revenue of $0.76M misses by $0.7M